Hot Features
プレミアム
登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。
- Marks successful completion of full enrollment of SAD cohorts and the first two MAD cohorts in the healthy volunteer study - Up to 10 adult participants with genetically confirmed Duchenne...
Satellos Bioscience Inc. (TSX:MSCL, OTCQB:MSCLF) (“Satellos”), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and...
Satellos Bioscience Inc. (TSX:MSCL, OTCQB:MSCLF) ("Satellos" or the "Company"), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle...
Satellos Bioscience Inc. (TSX: MSCL) (OTCQB: MSCLF) (“Satellos” or the “Company”), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle...
- Completed enrollment for SAT-3247 in Duchenne muscular dystrophy (DMD) in the first three (of five) single-ascending dose (SAD) cohorts with no safety concerns and initiated enrollment of first...
Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle...
- Analysis showed improvement in muscle morphology and increased levels of regeneration in muscle groups, including the diaphragm, quadriceps, and calf - No adverse events and no significant...
- The first healthy volunteer has been dosed in the first component of the Phase 1 study - Initial safety and pharmacokinetic data expected in Q4 2024 - Initiation of the second component of...
Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle...
Dosing of first participant in a Phase 1 clinical trial of SAT-3247 anticipated in Q3 2024 Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL, OTCQB: MSCLF), a public biotech...
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.04 | -4.49438202247 | 0.89 | 0.89 | 0.83 | 29500 | 0.86432928 | CS |
| 4 | 0.02 | 2.40963855422 | 0.83 | 0.89 | 0.81 | 48252 | 0.86461604 | CS |
| 12 | -0.01 | -1.16279069767 | 0.86 | 1.32 | 0.67 | 135299 | 0.88666159 | CS |
| 26 | 0.36 | 73.4693877551 | 0.49 | 1.32 | 0.45 | 114311 | 0.77295541 | CS |
| 52 | 0.23 | 37.0967741935 | 0.62 | 1.32 | 0.38 | 89597 | 0.69721721 | CS |
| 156 | 0.23 | 37.0967741935 | 0.62 | 1.32 | 0.38 | 89597 | 0.69721721 | CS |
| 260 | 0.23 | 37.0967741935 | 0.62 | 1.32 | 0.38 | 89597 | 0.69721721 | CS |
Backstabbed
45秒前
layton
2分前
manibiotech
2分前
WOW23P
2分前
IceCold8
2分前
manibiotech
2分前
Backstabbed
3分前
gdog
3分前
BigMoneySal
4分前
WarMachine
5分前
Backstabbed
6分前
newmedman
6分前
MartinLutherKing
7分前
valuemind
7分前
jondoeuk
7分前
MartinLutherKing
8分前
Backstabbed
9分前
Backstabbed
9分前
Backstabbed
10分前
ChartTRACKER
10分前
Backstabbed
10分前
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
